Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Other EventsItem 8.01 Other Events.
On October18, 2017, Trovagene,Inc. (the “Company”) issued a press release announcing positive data from preclinical research demonstrating synergy of PCM-075, its oral, highly-selective Polo-like Kinase 1 (PLK1) Inhibitor, in combination with abiraterone (Zytiga®). A copy of the press release is furnished as Exhibit99.1 to this Form8-K.
Item 9.01. Financial Statements and Exhibits
(d)Exhibits.
|
99.1 |
Press Release of Trovagene,Inc. dated October18, 2017 |
Trovagene, Inc. ExhibitEX-99.1 2 a17-22879_1ex99d1.htm EX-99.1 Exhibit 99.1 Trovagene’s PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga® (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells PCM-075 enhances activity of abiraterone in mCRPC tumors cells and may represent a novel treatment option to extend the benefit of anti-androgen therapy SAN DIEGO,…To view the full exhibit click here
About Trovagene,Inc. (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.
